Carfilzomib combinations demonstrate overall survival benefit in relapsed and refractory myeloma

Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis┬«) in combination with lenalidomide (Revlimid┬«) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…

Details